Vaginal atrophy can negatively impact your patients

Click here to watch our experts discuss
vaginal atrophy signs and symptoms

Half of all women who have gone through the menopause experience pain or discomfort from vaginal atrophy.1,2

Vaginal atrophy can have significant effects on women, impacting their welfare and relationships.1,2

My Blissel® Time to talk
Video Library

A library of discussions led by national experts Dr Anne Connolly, Dr Diana Mansour and Nurse Specialist Consultant Nikki Noble.
The videos cover a range of very useful, relevant and important topics including, the signs and symptoms of VA, how to make the diagnosis and the impact of vaginal atrophy on a patient’s quality of life.

Click here to open and play the videos

The challenge of getting your patient to talk about their symptoms

There are many reasons why women may feel that they cannot talk to their doctor about vaginal atrophy, including:3

  • Embarrassment
  • Feeling that there is no treatment for these symptoms
  • Thinking it is inappropriate to discuss these symptoms

Vaginal atrophy can present in many ways, including:4 

  • Itching
  • Burning
  • Dysuria
  • Dyspareunia
  • Vaginal dryness

Vaginal dryness

Dyspareunia

Itching

Dysuria

Burning

Click here to watch our experts discuss challenges in patient diagnosis

Prescribe Blissel® by brand for your patients. Blissel®is the first and only prescribable estriol containing gel for the treatment of vaginal atrophy5,6

Guidelines on the treatment of vaginal atrophy 

NICE guidelines provide clear direction that local therapy is preferable to systemic treatment for vaginal symptoms.7 Guidelines advocate to provide vaginal oestrogen to women to manage bothersome symptoms of vaginal atrophy.7

Despite clear guidelines, half of all women who experience genitourinary symptoms after the menopause have not received any treatment at all for their symptoms.8

Treating vaginal atrophy with Blissel®

Blissel® is an ultra low dose estriol vaginal gel containing 50 micrograms per dose (1 gram) of estriol, indicated for treating the symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women.5,6

For postmenopausal vaginal atrophy, the treatment has been shown to be well-tolerated and effective.6 Blissel® gives your patients a rapid improvement in their symptoms from the first days of treatment.9

Upcoming Webinars 2024

24th April

7pm to
9pm

Prescribing Precision – Medications for symptom relief with Dr Diana Mansour

  • Join us for an informative discussion about prescribing medications for Vaginal Atrophy symptom relief

To register your interest please click below:

Click Here To Find Out More

How BlisselⓇ
Works

Efficacy

Dosing

Ultra low dose estriol vaginal gel8,9

Prescribing and Adverse event reporting information for BlisselⓇ can be found here.

 Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com 

1. Nappi RE, Palacios S. Climacteric. 2014;17:3–9. 2. Moral E, et al. Menopause. 2018;25(12):1418-23.
3. Kagan R, et al. Drugs Aging. 2019;36:897–908. 4. Palmaa F, et al. Maturitas. 2018;108:18–23.
5. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics. 6. Cano A, et al. Menopause. 2012;19(10):1130-9.
7. NICE. Menopause: diagnosis and management (NG23). Available from: https://www.nice.org.uk/guidance/ng23/chapter/recommendations. Accessed July 2024. 8. NAMS position statement. Menopause. 2020;27(9):976-92.
9. Lázaro-Carrasco de la Fuente J, et al. J Menopausal Med. 2022;28(2):60-69.

Date of preparation: July 2024 | UK-BLS-528